```
=> File .Biotech
FILE 'MEDLINE' ENTERED AT 15:59:32 ON 21 JUL 2009

FILE 'CAPLUS' ENTERED AT 15:59:32 ON 21 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:59:32 ON 21 JUL 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 15:59:32 ON 21 JUL 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'EMBASE' ENTERED AT 15:59:32 ON 21 JUL 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 15:59:32 ON 21 JUL 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:59:32 ON 21 JUL 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

=> s (Histidine Tag or His Tag or Poly His Tag)
L1       24075 (HISTIDINE TAG OR HIS TAG OR POLY HIS TAG)

=> s L1 and (cleav?)
L2       13726 L1 AND (CLEAV?)

=> s L2 and (transitional metal)
L3          13 L2 AND (TRANSITIONAL METAL)

=> s L2 and (metal ions)
L4        1926 L2 AND (METAL IONS)

=> s L3 and L4
L5           8 L3 AND L4

=> s L3 and (buffer)
L6          13 L3 AND (BUFFER)

=> s L6 and (reducing agent)
L7           2 L6 AND (REDUCING AGENT)

=> s L6 and (oxidizing agent)
L8           0 L6 AND (OXIDIZING AGENT)

=> s L6 and (Copper or Cu or Cobalt or Co)
L9          13 L6 AND (COPPER OR CU OR COBALT OR CO)

=> s L9 and (hydrogen peroxid or H2O2)
L10          0 L9 AND (HYDROGEN PEROXID OR H2O2)

=> s L9 and (ascorbate)
L11          0 L9 AND (ASCORBATE)

=> s L3 and (hydrgen peroxide or ascorbate)
L12          0 L3 AND (HYDRGEN PEROXIDE OR ASCORBATE)

=> s L3 and (oxidizing agent or agents)
L13         13 L3 AND (OXIDIZING AGENT OR AGENTS)

=> s L13 and (reducing agent or agents)
L14         13 L13 AND (REDUCING AGENT OR AGENTS)

=> s L13 and L14
L15         13 L13 AND L14

=> s l15 and (hydrogen peroxide)
L16          5 L15 AND (HYDROGEN PEROXIDE)

=> s L15 and (ascorbate)
L17          0 L15 AND (ASCORBATE)

=> s L15 and (Copper or Cu or Cobalt or Co)
L18         13 L15 AND (COPPER OR CU OR COBALT OR CO)

=> dup rem L18
```

```
PROCESSING COMPLETED FOR L18
L19            13 DUP REM L18 (0 DUPLICATES REMOVED)

=> d l19 1-13 bib ab

L19  ANSWER 1 OF 13  USPATFULL on STN
AN     2009:172634  USPATFULL <<LOGINID::20090721>>
TI     Antibodies to MT-SP1 serine  protease
IN     Craik, Charles S., San Francisco, CA, UNITED STATES
       Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
       Shuman, Marc, San Francisco, CA, UNITED STATES
PA     The Regents of the University of California (U.S. corporation)
PI     US 20090155248       A1  20090618
AI     US 2008-14067        A1  20080114 (12)
RLI    Continuation of Ser. No. US 2005-254185, filed on 18 Oct 2005, ABANDONED
       Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, Pat. No.
       US 7030231
DT     Utility
FS     APPLICATION
LREP   WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
       94304-1050, US
CLMN   Number of Claims: 23
ECL    Exemplary Claim: 1-80
DRWN   8 Drawing Page(s)
LN.CNT 5204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     This invention provides a novel membrane-type serine protease
       (designated MT-SP1) elevated expression of which is associated with
       cancer. In one embodiment, this invention provides a method obtaining a
       prognosis or of detecting or staging a cancer in an organism. The method
       involves providing a biological sample from the organism and detecting
       the level of a membrane type serine protease 1 (MT-SP1) in the sample,
       where an elevated level of the membrane-type serine protease, as
       compared to the level of the protease in a biological sample from a
       normal healthy organism indicates the presence or stage of the cancer.

L19  ANSWER 2 OF 13  USPATFULL on STN
AN     2009:145929  USPATFULL <<LOGINID::20090721>>
TI     SIALIC ACID ABC TRANSPORTERS IN PROKARYOTES THERAPEUTIC TARGETS
IN     Gibson, Bradford W., Berkeley, CA, UNITED STATES
       Munson, Robert S., Hilliard, OH, UNITED STATES
       Post, Deborah M., Fairfax, CA, UNITED STATES
PA     BUCK INSTITUTE, Novato, CA, UNITED STATES (U.S. corporation)
PI     US 20090131524       A1  20090521
AI     US 2006-916975       A1  20060531 (11)
       WO 2006-US21202          20060531
                                20081222  PCT 371 date
PRAI   US 2005-689151P          20050607 (60)
DT     Utility
FS     APPLICATION
LREP   Weaver Austin Villeneuve & Sampson LLP, P.O. BOX 70250, OAKLAND, CA,
       94612-0250, US
CLMN   Number of Claims: 39
ECL    Exemplary Claim: 1
DRWN   5 Drawing Page(s)
LN.CNT 2903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     This invention provides a novel bacterial sialic acid transporter that
       is a member of the family of ABC transporters. The transporter is a
       useful target for pharmaceuticals.

L19  ANSWER 3 OF 13  USPATFULL on STN
AN     2008:58714  USPATFULL <<LOGINID::20090721>>
TI     MT-SP1 polypeptides
IN     Craik, Charles S., San Francisco, CA, UNITED STATES
       Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
       Shuman, Marc, San Francisco, CA, UNITED STATES
PA     The Regents of the University of California (U.S. corporation)
PI     US 20080051559       A1  20080228
AI     US 2007-669725       A1  20070131 (11)
RLI    Division of Ser. No. US 2005-253869, filed on 18 Oct 2005, GRANTED, Pat.
       No. US 7227009 Division of Ser. No. US 1999-410362, filed on 30 Sep
       1999, GRANTED, Pat. No. US 7030231
DT     Utility
FS     APPLICATION
LREP   WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
       94304-1050, US
CLMN   Number of Claims: 16
ECL    Exemplary Claim: 1-80
```

DRWN 8 Drawing Page(s)
LN.CNT 5329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

L19 ANSWER 4 OF 13 USPATFULL on STN
AN 2007:183634 USPATFULL <<LOGINID::20090721>>
TI Method for assembling a polymer-biologic delivery composition
IN Turnell, William G., Del Mar, CA, UNITED STATES
Parcher, Benjamin W., San Diego, CA, UNITED STATES
Charles, Catherine H., Encinitas, CA, UNITED STATES
Pabba, Chittari, San Diego, CA, UNITED STATES
Vitiello, Maria A., La Jolla, CA, UNITED STATES
PA MediVas, LLC, San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20070160622 A1 20070712
AI US 2006-636230 A1 20061207 (11)
PRAI US 2005-748486P 20051207 (60)
US 2006-858173P 20061110 (60)
DT Utility
FS APPLICATION
LREP DLA PIPER US LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133, US
CLMN Number of Claims: 71
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 4175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A one-step method for assembly of delivery compositions for one or more antigens or therapeutic biologics is based on non-covalent affinity capture of molecules from solution using a biodegradable polymer having functional groups to which the affinity ligand binds. The polymer-bound affinity complex, which includes the molecule(s) of interest is then recovered from the reaction solution, for example, by size exclusion filtration, to yield the assembled delivery composition. The affinity ligand can be a monoclonal antibody or a metal affinity ligand with bound metal transition ion. The assembled delivery compositions can be formulated as polymer particles, which can then be lyophilized and reconstituted for in vivo delivery of the non-covalently complexed antigen(s) or therapeutic biologic(s) with substantial native activity.

L19 ANSWER 5 OF 13 USPATFULL on STN
AN 2006:308189 USPATFULL <<LOGINID::20090721>>
TI Methods of high-throughput screening for internalizing antibodies
IN Marks, James D., Kensington, CA, UNITED STATES
Nielsen, Ulrik B., Brookline, MA, UNITED STATES
Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20060263801 A1 20061123
AI US 2006-361312 A1 20060224 (11)
RLI Division of Ser. No. US 2001-981636, filed on 16 Oct 2001, GRANTED, Pat. No. US 7045283
PRAI US 2000-241279P 20001018 (60)
DT Utility
FS APPLICATION
LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1-43
DRWN 8 Drawing Page(s)
LN.CNT 2216
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.

L19 ANSWER 6 OF 13 USPATFULL on STN

AN 2006:280987 USPATFULL <<LOGINID::20090721>>
TI COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND OTHER MATERIALS, AND METHODS OF MAKING AND USING THE SAME
IN Bolotin, Elijah M., Kirkland, WA, UNITED STATES
PI US 20060239924 A1 20061026
AI US 2006-428803 A1 20060705 (11)
RLI Continuation of Ser. No. US 2003-378100, filed on 27 Feb 2003, PENDING
PRAI US 2002-360350P 20020227 (60)
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P.O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 2631
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In part, the present invention is directed to biocompatible compositions comprising a carrier with a first metal binding domain, a metal ion, an active agent with second metal binding domain and optionally a protective chain covalently attached to the polymeric carrier.

L19 ANSWER 7 OF 13 USPATFULL on STN
AN 2006:124247 USPATFULL <<LOGINID::20090721>>
TI MT-SP1 POLYNUCLEOTIDES AND POLYPEPTIDES
IN Craik, Charles S., San Francisco, CA, UNITED STATES
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
Shuman, Marc, San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20060104979 A1 20060518
US 7227009 B2 20070605
AI US 2005-253869 A1 20051018 (11)
RLI Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-80
DRWN 8 Drawing Page(s)
LN.CNT 5095
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

L19 ANSWER 8 OF 13 USPATFULL on STN
AN 2006:117783 USPATFULL <<LOGINID::20090721>>
TI MT-SP1 serine protease
IN Craik, Charles S., San Francisco, CA, UNITED STATES
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
Shuman, Marc, San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20060099625 A1 20060511
AI US 2005-254185 A1 20051018 (11)
RLI Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-80
DRWN 8 Drawing Page(s)
LN.CNT 5119
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

L19 ANSWER 9 OF 13 USPATFULL on STN
AN 2006:110718 USPATFULL <<LOGINID::20090721>>
TI Compositions for treatment with glucagon-like peptide, and methods of making and using the same
IN Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES
PI US 20060093660 A1 20060504
AI US 2005-266002 A1 20051103 (11)
RLI Continuation of Ser. No. US 2005-112879, filed on 22 Apr 2005, PENDING Continuation-in-part of Ser. No. US 2003-378100, filed on 27 Feb 2003, PENDING
PRAI US 2004-564710P 20040423 (60)
US 2002-360350P 20020227 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1.

L19 ANSWER 10 OF 13 USPATFULL on STN
AN 2006:95221 USPATFULL <<LOGINID::20090721>>
TI Membrane type serine protease 1 (MT-SP1) and uses thereof
IN Craik, Charles S., San Francisco, CA, UNITED STATES
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
Shuman, Marc, San Francisco, CA, UNITED STATES
PA Catalyst Biosciences, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 7030231 B1 20060418
AI US 1999-410362 19990930 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Helms, Larry R.; Assistant Examiner: Yu, Misook
LREP Wilson Sonsini Goodrich & Rosati
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 5132
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

L19 ANSWER 11 OF 13 USPATFULL on STN
AN 2005:298594 USPATFULL <<LOGINID::20090721>>
TI Compositions for treatment with glucagon-like peptide, and methods of making and using the same
IN Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES
PI US 20050260259 A1 20051124
AI US 2005-112879 A1 20050422 (11)
PRAI US 2004-564710P 20040423 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3100
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1.

L19 ANSWER 12 OF 13 USPATFULL on STN
AN 2003:319225 USPATFULL <<LOGINID::20090721>>
TI Compositions for delivery of therapeutics and other materials, and methods of making and using the same
IN Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES

```
PI     US 20030224974          A1  20031204
       US 7138105              B2  20061121
AI     US 2003-378100          A1  20030227 (10)
PRAI   US 2002-360350P             20020227 (60)
DT     Utility
FS     APPLICATION
LREP   Patent Group, Foley Hoag LLP, World Trade Center West, 155 Seaport
       Blvd., Boston, MA, 02210-2600
CLMN   Number of Claims: 32
ECL    Exemplary Claim: 1
DRWN   4 Drawing Page(s)
LN.CNT 2657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     In part, the present invention is directed to compositions comprising a
       carrier with a metal binding domain, a metal ion, and an active agent.

L19  ANSWER 13 OF 13  USPATFULL on STN
AN     2002:322479  USPATFULL <<LOGINID::20090721>>
TI     Methods of high-throughput screening for internalizing antibodies
IN     Marks, James D., Kensington, CA, UNITED STATES
       Nielsen, Ulrik B., Brookline, MA, UNITED STATES
       Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PI     US 20020182643          A1  20021205
       US 7045283              B2  20060516
AI     US 2001-981636          A1  20011016 (9)
PRAI   US 2000-241279P             20001018 (60)
DT     Utility
FS     APPLICATION
LREP   QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA,
       94501
CLMN   Number of Claims: 72
ECL    Exemplary Claim: 1
DRWN   8 Drawing Page(s)
LN.CNT 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     This invention provides methods of identifying ligands that are
       internalized into a cell. The methods typically involve i) contacting
       the cell with a reporter non-covalently coupled to a ligand; ii)
       dissociating the reporter from the ligand and removing dissociated
       reporter from the surface of the cell; and iii) detecting the reporter
       within said cell (if any is present) where the presence of the reporter
       within said cell indicates that the ligand binds to an internalizing
       receptor and is internalized.


=> d his

     (FILE 'HOME' ENTERED AT 15:59:11 ON 21 JUL 2009)

     FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'
     ENTERED AT 15:59:32 ON 21 JUL 2009
L1        24075 S (HISTIDINE TAG OR HIS TAG OR POLY HIS TAG)
L2        13726 S L1 AND (CLEAV?)
L3           13 S L2 AND (TRANSITIONAL METAL)
L4         1926 S L2 AND (METAL IONS)
L5            8 S L3 AND L4
L6           13 S L3 AND (BUFFER)
L7            2 S L6 AND (REDUCING AGENT)
L8            0 S L6 AND (OXIDIZING AGENT)
L9           13 S L6 AND (COPPER OR CU OR COBALT OR CO)
L10           0 S L9 AND (HYDROGEN PEROXID OR H2O2)
L11           0 S L9 AND (ASCORBATE)
L12           0 S L3 AND (HYDRGEN PEROXIDE OR ASCORBATE)
L13          13 S L3 AND (OXIDIZING AGENT OR AGENTS)
L14          13 S L13 AND (REDUCING AGENT OR AGENTS)
L15          13 S L13 AND L14
L16           5 S L15 AND (HYDROGEN PEROXIDE)
L17           0 S L15 AND (ASCORBATE)
L18          13 S L15 AND (COPPER OR CU OR COBALT OR CO)
L19          13 DUP REM L18 (0 DUPLICATES REMOVED)

=> d L3 1-13 bib ab

L3   ANSWER 1 OF 13  USPATFULL on STN
AN     2009:172634  USPATFULL <<LOGINID::20090721>>
TI     Antibodies to MT-SP1 serine  protease
IN     Craik, Charles S., San Francisco, CA, UNITED STATES
       Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
       Shuman, Marc, San Francisco, CA, UNITED STATES
```

PA The Regents of the University of California (U.S. corporation)
PI US 20090155248 A1 20090618
AI US 2008-14067 A1 20080114 (12)
RLI Continuation of Ser. No. US 2005-254185, filed on 18 Oct 2005, ABANDONED Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, Pat. No. US 7030231
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1-80
DRWN 8 Drawing Page(s)
LN.CNT 5204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

L3 ANSWER 2 OF 13 USPATFULL on STN
AN 2009:145929 USPATFULL <<LOGINID::20090721>>
TI SIALIC ACID ABC TRANSPORTERS IN PROKARYOTES THERAPEUTIC TARGETS
IN Gibson, Bradford W., Berkeley, CA, UNITED STATES
Munson, Robert S., Hilliard, OH, UNITED STATES
Post, Deborah M., Fairfax, CA, UNITED STATES
PA BUCK INSTITUTE, Novato, CA, UNITED STATES (U.S. corporation)
PI US 20090131524 A1 20090521
AI US 2006-916975 A1 20060531 (11)
WO 2006-US21202 20060531
20081222 PCT 371 date
PRAI US 2005-689151P 20050607 (60)
DT Utility
FS APPLICATION
LREP Weaver Austin Villeneuve & Sampson LLP, P.O. BOX 70250, OAKLAND, CA, 94612-0250, US
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel bacterial sialic acid transporter that is a member of the family of ABC transporters. The transporter is a useful target for pharmaceuticals.

L3 ANSWER 3 OF 13 USPATFULL on STN
AN 2008:58714 USPATFULL <<LOGINID::20090721>>
TI MT-SP1 polypeptides
IN Craik, Charles S., San Francisco, CA, UNITED STATES
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
Shuman, Marc, San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20080051559 A1 20080228
AI US 2007-669725 A1 20070131 (11)
RLI Division of Ser. No. US 2005-253869, filed on 18 Oct 2005, GRANTED, Pat. No. US 7227009 Division of Ser. No. US 1999-410362, filed on 30 Sep 1999, GRANTED, Pat. No. US 7030231
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1-80
DRWN 8 Drawing Page(s)
LN.CNT 5329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a

normal healthy organism indicates the presence or stage of the cancer.

L3 ANSWER 4 OF 13 USPATFULL on STN
AN 2007:183634 USPATFULL <<LOGINID::20090721>>
TI Method for assembling a polymer-biologic delivery composition
IN Turnell, William G., Del Mar, CA, UNITED STATES
Parcher, Benjamin W., San Diego, CA, UNITED STATES
Charles, Catherine H., Encinitas, CA, UNITED STATES
Pabba, Chittari, San Diego, CA, UNITED STATES
Vitiello, Maria A., La Jolla, CA, UNITED STATES
PA MediVas, LLC, San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20070160622 A1 20070712
AI US 2006-636230 A1 20061207 (11)
PRAI US 2005-748486P 20051207 (60)
US 2006-858173P 20061110 (60)
DT Utility
FS APPLICATION
LREP DLA PIPER US LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133, US
CLMN Number of Claims: 71
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 4175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A one-step method for assembly of delivery compositions for one or more antigens or therapeutic biologics is based on non-covalent affinity capture of molecules from solution using a biodegradable polymer having functional groups to which the affinity ligand binds. The polymer-bound affinity complex, which includes the molecule(s) of interest is then recovered from the reaction solution, for example, by size exclusion filtration, to yield the assembled delivery composition. The affinity ligand can be a monoclonal antibody or a metal affinity ligand with bound metal transition ion. The assembled delivery compositions can be formulated as polymer particles, which can then be lyophilized and reconstituted for in vivo delivery of the non-covalently complexed antigen(s) or therapeutic biologic(s) with substantial native activity.

L3 ANSWER 5 OF 13 USPATFULL on STN
AN 2006:308189 USPATFULL <<LOGINID::20090721>>
TI Methods of high-throughput screening for internalizing antibodies
IN Marks, James D., Kensington, CA, UNITED STATES
Nielsen, Ulrik B., Brookline, MA, UNITED STATES
Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20060263801 A1 20061123
AI US 2006-361312 A1 20060224 (11)
RLI Division of Ser. No. US 2001-981636, filed on 16 Oct 2001, GRANTED, Pat. No. US 7045283
PRAI US 2000-241279P 20001018 (60)
DT Utility
FS APPLICATION
LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1-43
DRWN 8 Drawing Page(s)
LN.CNT 2216
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.

L3 ANSWER 6 OF 13 USPATFULL on STN
AN 2006:280987 USPATFULL <<LOGINID::20090721>>
TI COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND OTHER MATERIALS, AND METHODS OF MAKING AND USING THE SAME
IN Bolotin, Elijah M., Kirkland, WA, UNITED STATES
PI US 20060239924 A1 20061026
AI US 2006-428803 A1 20060705 (11)
RLI Continuation of Ser. No. US 2003-378100, filed on 27 Feb 2003, PENDING
PRAI US 2002-360350P 20020227 (60)
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P.O. BOX 5257, NEW YORK, NY, 10150-5257, US

CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 2631
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In part, the present invention is directed to biocompatible compositions comprising a carrier with a first metal binding domain, a metal ion, an active agent with second metal binding domain and optionally a protective chain covalently attached to the polymeric carrier.

L3 ANSWER 7 OF 13 USPATFULL on STN
AN 2006:124247 USPATFULL <<LOGINID::20090721>>
TI MT-SP1 POLYNUCLEOTIDES AND POLYPEPTIDES
IN Craik, Charles S., San Francisco, CA, UNITED STATES
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
Shuman, Marc, San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20060104979 A1 20060518
US 7227009 B2 20070605
AI US 2005-253869 A1 20051018 (11)
RLI Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-80
DRWN 8 Drawing Page(s)
LN.CNT 5095
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

L3 ANSWER 8 OF 13 USPATFULL on STN
AN 2006:117783 USPATFULL <<LOGINID::20090721>>
TI MT-SP1 serine protease
IN Craik, Charles S., San Francisco, CA, UNITED STATES
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
Shuman, Marc, San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20060099625 A1 20060511
AI US 2005-254185 A1 20051018 (11)
RLI Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-80
DRWN 8 Drawing Page(s)
LN.CNT 5119
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

L3 ANSWER 9 OF 13 USPATFULL on STN
AN 2006:110718 USPATFULL <<LOGINID::20090721>>
TI Compositions for treatment with glucagon-like peptide, and methods of making and using the same
IN Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES
PI US 20060093660 A1 20060504
AI US 2005-266002 A1 20051103 (11)
RLI Continuation of Ser. No. US 2005-112879, filed on 22 Apr 2005, PENDING
Continuation-in-part of Ser. No. US 2003-378100, filed on 27 Feb 2003, PENDING

PRAI US 2004-564710P 20040423 (60)
      US 2002-360350P 20020227 (60)
DT   Utility
FS   APPLICATION
LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
CLMN Number of Claims: 22
ECL   Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1.

L3 ANSWER 10 OF 13 USPATFULL on STN
AN   2006:95221 USPATFULL <<LOGINID::20090721>>
TI   Membrane type serine protease 1 (MT-SP1) and uses thereof
IN   Craik, Charles S., San Francisco, CA, UNITED STATES
      Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
      Shuman, Marc, San Francisco, CA, UNITED STATES
PA   Catalyst Biosciences, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI   US 7030231 B1 20060418
AI   US 1999-410362 19990930 (9)
DT   Utility
FS   GRANTED
EXNAM Primary Examiner: Helms, Larry R.; Assistant Examiner: Yu, Misook
LREP Wilson Sonsini Goodrich & Rosati
CLMN Number of Claims: 6
ECL   Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 5132
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

L3 ANSWER 11 OF 13 USPATFULL on STN
AN   2005:298594 USPATFULL <<LOGINID::20090721>>
TI   Compositions for treatment with glucagon-like peptide, and methods of making and using the same
IN   Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES
PI   US 20050260259 A1 20051124
AI   US 2005-112879 A1 20050422 (11)
PRAI US 2004-564710P 20040423 (60)
DT   Utility
FS   APPLICATION
LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
CLMN Number of Claims: 22
ECL   Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3100
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1.

L3 ANSWER 12 OF 13 USPATFULL on STN
AN   2003:319225 USPATFULL <<LOGINID::20090721>>
TI   Compositions for delivery of therapeutics and other materials, and methods of making and using the same
IN   Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES
PI   US 20030224974 A1 20031204
      US 7138105 B2 20061121
AI   US 2003-378100 A1 20030227 (10)
PRAI US 2002-360350P 20020227 (60)
DT   Utility
FS   APPLICATION
LREP Patent Group, Foley Hoag LLP, World Trade Center West, 155 Seaport Blvd., Boston, MA, 02210-2600
CLMN Number of Claims: 32
ECL   Exemplary Claim: 1
DRWN 4 Drawing Page(s)

```
LN.CNT 2657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      In part, the present invention is directed to compositions comprising a
        carrier with a metal binding domain, a metal ion, and an active agent.

L3   ANSWER 13 OF 13  USPATFULL on STN
AN      2002:322479  USPATFULL <<LOGINID::20090721>>
TI      Methods of high-throughput screening for internalizing antibodies
IN      Marks, James D., Kensington, CA, UNITED STATES
        Nielsen, Ulrik B., Brookline, MA, UNITED STATES
        Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PI      US 20020182643      A1  20021205
        US 7045283          B2  20060516
AI      US 2001-981636      A1  20011016 (9)
PRAI    US 2000-241279P         20001018 (60)
DT      Utility
FS      APPLICATION
LREP    QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA,
        94501
CLMN    Number of Claims: 72
ECL     Exemplary Claim: 1
DRWN    8 Drawing Page(s)
LN.CNT 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      This invention provides methods of identifying ligands that are
        internalized into a cell. The methods typically involve i) contacting
        the cell with a reporter non-covalently coupled to a ligand; ii)
        dissociating the reporter from the ligand and removing dissociated
        reporter from the surface of the cell; and iii) detecting the reporter
        within said cell (if any is present) where the presence of the reporter
        within said cell indicates that the ligand binds to an internalizing
        receptor and is internalized.


=> d L5 1-8 bib ab

L5   ANSWER 1 OF 8  USPATFULL on STN
AN      2009:145929  USPATFULL <<LOGINID::20090721>>
TI      SIALIC ACID ABC TRANSPORTERS IN PROKARYOTES THERAPEUTIC TARGETS
IN      Gibson, Bradford W., Berkeley, CA, UNITED STATES
        Munson, Robert S., Hilliard, OH, UNITED STATES
        Post, Deborah M., Fairfax, CA, UNITED STATES
PA      BUCK INSTITUTE, Novato, CA, UNITED STATES (U.S. corporation)
PI      US 20090131524      A1  20090521
AI      US 2006-916975      A1  20060531 (11)
        WO 2006-US21202         20060531
                                20081222  PCT 371 date
PRAI    US 2005-689151P         20050607 (60)
DT      Utility
FS      APPLICATION
LREP    Weaver Austin Villeneuve & Sampson LLP, P.O. BOX 70250, OAKLAND, CA,
        94612-0250, US
CLMN    Number of Claims: 39
ECL     Exemplary Claim: 1
DRWN    5 Drawing Page(s)
LN.CNT 2903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      This invention provides a novel bacterial sialic acid transporter that
        is a member of the family of ABC transporters. The transporter is a
        useful target for pharmaceuticals.

L5   ANSWER 2 OF 8  USPATFULL on STN
AN      2007:183634  USPATFULL <<LOGINID::20090721>>
TI      Method for assembling a polymer-biologic delivery composition
IN      Turnell, William G., Del Mar, CA, UNITED STATES
        Parcher, Benjamin W., San Diego, CA, UNITED STATES
        Charles, Catherine H., Encinitas, CA, UNITED STATES
        Pabba, Chittari, San Diego, CA, UNITED STATES
        Vitiello, Maria A., La Jolla, CA, UNITED STATES
PA      MediVas, LLC, San Diego, CA, UNITED STATES (U.S. corporation)
PI      US 20070160622      A1  20070712
AI      US 2006-636230      A1  20061207 (11)
PRAI    US 2005-748486P         20051207 (60)
        US 2006-858173P         20061110 (60)
DT      Utility
FS      APPLICATION
LREP    DLA PIPER US LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA,
        92121-2133, US
CLMN    Number of Claims: 71
```

ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 4175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A one-step method for assembly of delivery compositions for one or more antigens or therapeutic biologics is based on non-covalent affinity capture of molecules from solution using a biodegradable polymer having functional groups to which the affinity ligand binds. The polymer-bound affinity complex, which includes the molecule(s) of interest is then recovered from the reaction solution, for example, by size exclusion filtration, to yield the assembled delivery composition. The affinity ligand can be a monoclonal antibody or a metal affinity ligand with bound metal transition ion. The assembled delivery compositions can be formulated as polymer particles, which can then be lyophilized and reconstituted for in vivo delivery of the non-covalently complexed antigen(s) or therapeutic biologic(s) with substantial native activity.

L5 ANSWER 3 OF 8 USPATFULL on STN
AN 2006:308189 USPATFULL <<LOGINID::20090721>>
TI Methods of high-throughput screening for internalizing antibodies
IN Marks, James D., Kensington, CA, UNITED STATES
Nielsen, Ulrik B., Brookline, MA, UNITED STATES
Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20060263801 A1 20061123
AI US 2006-361312 A1 20060224 (11)
RLI Division of Ser. No. US 2001-981636, filed on 16 Oct 2001, GRANTED, Pat. No. US 7045283
PRAI US 2000-241279P 20001018 (60)
DT Utility
FS APPLICATION
LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1-43
DRWN 8 Drawing Page(s)
LN.CNT 2216
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.

L5 ANSWER 4 OF 8 USPATFULL on STN
AN 2006:280987 USPATFULL <<LOGINID::20090721>>
TI COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND OTHER MATERIALS, AND METHODS OF MAKING AND USING THE SAME
IN Bolotin, Elijah M., Kirkland, WA, UNITED STATES
PI US 20060239924 A1 20061026
AI US 2006-428803 A1 20060705 (11)
RLI Continuation of Ser. No. US 2003-378100, filed on 27 Feb 2003, PENDING
PRAI US 2002-360350P 20020227 (60)
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P.O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 2631
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In part, the present invention is directed to biocompatible compositions comprising a carrier with a first metal binding domain, a metal ion, an active agent with second metal binding domain and optionally a protective chain covalently attached to the polymeric carrier.

L5 ANSWER 5 OF 8 USPATFULL on STN
AN 2006:110718 USPATFULL <<LOGINID::20090721>>
TI Compositions for treatment with glucagon-like peptide, and methods of making and using the same
IN Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES
PI US 20060093660 A1 20060504
AI US 2005-266002 A1 20051103 (11)
RLI Continuation of Ser. No. US 2005-112879, filed on 22 Apr 2005, PENDING
Continuation-in-part of Ser. No. US 2003-378100, filed on 27 Feb 2003, PENDING

PRAI US 2004-564710P 20040423 (60)
      US 2002-360350P 20020227 (60)
DT   Utility
FS   APPLICATION
LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
CLMN Number of Claims: 22
ECL   Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1.

L5 ANSWER 6 OF 8 USPATFULL on STN
AN   2005:298594 USPATFULL <<LOGINID::20090721>>
TI   Compositions for treatment with glucagon-like peptide, and methods of making and using the same
IN   Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES
PI   US 20050260259 A1 20051124
AI   US 2005-112879 A1 20050422 (11)
PRAI US 2004-564710P 20040423 (60)
DT   Utility
FS   APPLICATION
LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
CLMN Number of Claims: 22
ECL   Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3100
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1.

L5 ANSWER 7 OF 8 USPATFULL on STN
AN   2003:319225 USPATFULL <<LOGINID::20090721>>
TI   Compositions for delivery of therapeutics and other materials, and methods of making and using the same
IN   Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES
PI   US 20030224974 A1 20031204
      US 7138105 B2 20061121
AI   US 2003-378100 A1 20030227 (10)
PRAI US 2002-360350P 20020227 (60)
DT   Utility
FS   APPLICATION
LREP Patent Group, Foley Hoag LLP, World Trade Center West, 155 Seaport Blvd., Boston, MA, 02210-2600
CLMN Number of Claims: 32
ECL   Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 2657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and an active agent.

L5 ANSWER 8 OF 8 USPATFULL on STN
AN   2002:322479 USPATFULL <<LOGINID::20090721>>
TI   Methods of high-throughput screening for internalizing antibodies
IN   Marks, James D., Kensington, CA, UNITED STATES
      Nielsen, Ulrik B., Brookline, MA, UNITED STATES
      Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PI   US 20020182643 A1 20021205
      US 7045283 B2 20060516
AI   US 2001-981636 A1 20011016 (9)
PRAI US 2000-241279P 20001018 (60)
DT   Utility
FS   APPLICATION
LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501
CLMN Number of Claims: 72
ECL   Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter

within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.

=> d L7 1-2 bib ab

L7 ANSWER 1 OF 2 USPATFULL on STN
AN 2006:308189 USPATFULL <<LOGINID::20090721>>
TI Methods of high-throughput screening for internalizing antibodies
IN Marks, James D., Kensington, CA, UNITED STATES
Nielsen, Ulrik B., Brookline, MA, UNITED STATES
Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20060263801 A1 20061123
AI US 2006-361312 A1 20060224 (11)
RLI Division of Ser. No. US 2001-981636, filed on 16 Oct 2001, GRANTED, Pat. No. US 7045283
PRAI US 2000-241279P 20001018 (60)
DT Utility
FS APPLICATION
LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1-43
DRWN 8 Drawing Page(s)
LN.CNT 2216
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.

L7 ANSWER 2 OF 2 USPATFULL on STN
AN 2002:322479 USPATFULL <<LOGINID::20090721>>
TI Methods of high-throughput screening for internalizing antibodies
IN Marks, James D., Kensington, CA, UNITED STATES
Nielsen, Ulrik B., Brookline, MA, UNITED STATES
Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PI US 20020182643 A1 20021205
US 7045283 B2 20060516
AI US 2001-981636 A1 20011016 (9)
PRAI US 2000-241279P 20001018 (60)
DT Utility
FS APPLICATION
LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.

=> d L16 1-5 bib ab

L16 ANSWER 1 OF 5 USPATFULL on STN
AN 2009:172634 USPATFULL <<LOGINID::20090721>>
TI Antibodies to MT-SP1 serine protease
IN Craik, Charles S., San Francisco, CA, UNITED STATES
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
Shuman, Marc, San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20090155248 A1 20090618
AI US 2008-14067 A1 20080114 (12)
RLI Continuation of Ser. No. US 2005-254185, filed on 18 Oct 2005, ABANDONED
Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, Pat. No.

US 7030231
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1-80
DRWN 8 Drawing Page(s)
LN.CNT 5204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

L16 ANSWER 2 OF 5 USPATFULL on STN
AN 2008:58714 USPATFULL <<LOGINID::20090721>>
TI MT-SP1 polypeptides
IN Craik, Charles S., San Francisco, CA, UNITED STATES
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
Shuman, Marc, San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20080051559 A1 20080228
AI US 2007-669725 A1 20070131 (11)
RLI Division of Ser. No. US 2005-253869, filed on 18 Oct 2005, GRANTED, Pat. No. US 7227009 Division of Ser. No. US 1999-410362, filed on 30 Sep 1999, GRANTED, Pat. No. US 7030231
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1-80
DRWN 8 Drawing Page(s)
LN.CNT 5329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

L16 ANSWER 3 OF 5 USPATFULL on STN
AN 2006:124247 USPATFULL <<LOGINID::20090721>>
TI MT-SP1 POLYNUCLEOTIDES AND POLYPEPTIDES
IN Craik, Charles S., San Francisco, CA, UNITED STATES
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
Shuman, Marc, San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20060104979 A1 20060518
US 7227009 B2 20070605
AI US 2005-253869 A1 20051018 (11)
RLI Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-80
DRWN 8 Drawing Page(s)
LN.CNT 5095
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a

normal healthy organism indicates the presence or stage of the cancer.

L16 ANSWER 4 OF 5 USPATFULL on STN
AN 2006:117783 USPATFULL <<LOGINID::20090721>>
TI MT-SP1 serine protease
IN Craik, Charles S., San Francisco, CA, UNITED STATES
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
Shuman, Marc, San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20060099625 A1 20060511
AI US 2005-254185 A1 20051018 (11)
RLI Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-80
DRWN 8 Drawing Page(s)
LN.CNT 5119
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

L16 ANSWER 5 OF 5 USPATFULL on STN
AN 2006:95221 USPATFULL <<LOGINID::20090721>>
TI Membrane type serine protease 1 (MT-SP1) and uses thereof
IN Craik, Charles S., San Francisco, CA, UNITED STATES
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
Shuman, Marc, San Francisco, CA, UNITED STATES
PA Catalyst Biosciences, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 7030231 B1 20060418
AI US 1999-410362 19990930 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Helms, Larry R.; Assistant Examiner: Yu, Misook
LREP Wilson Sonsini Goodrich & Rosati
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 5132
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 16:13:34 ON 21 JUL 2009